Oral Prednisolone Dosing for Ulcerative Colitis Flare
For moderate-to-severe ulcerative colitis flares, start prednisolone 40 mg once daily and taper over 6-8 weeks. This is the standard evidence-based regimen endorsed by the most recent British Society of Gastroenterology guidelines 1.
Initial Dosing
- Start with 40 mg prednisolone once daily 2
- Take as a single daily dose (more effective than split dosing and causes less adrenal suppression) 2
- Evidence shows 40 mg is more effective than 20 mg/day, but doses above 40-60 mg/day provide no additional benefit and increase adverse effects 2, 1
Tapering Schedule
Reduce by 5 mg per week over 6-8 weeks 2. This gradual taper minimizes relapse risk while limiting steroid exposure. More rapid reduction is associated with early relapse 3.
A typical taper would be:
- Weeks 1-2: 40 mg daily
- Week 3: 35 mg daily
- Week 4: 30 mg daily
- Week 5: 25 mg daily
- Week 6: 20 mg daily
- Week 7: 15 mg daily
- Week 8: 10 mg daily
- Week 9: 5 mg daily
- Week 10: Stop
Monitoring Response and Treatment Escalation
Assess response at 2 weeks 2. Improvements in clinical and endoscopic disease activity should be evident within 2 weeks of starting prednisolone 40 mg/day 2.
If no response after 2 weeks:
- Consider treatment escalation to biologics (anti-TNF, vedolizumab, ustekinumab) or small molecules (JAK inhibitors, S1P modulators) 1
- Admit to hospital if systemically unwell (fever, severe pain, significant anemia, generally unwell) 2
Important Caveats
Do not use prednisolone for maintenance therapy 1. Corticosteroids are effective for induction but inappropriate for long-term maintenance due to adverse effects.
Approximately 50% of patients experience short-term adverse effects including acne, edema, sleep and mood disturbance, glucose intolerance, and dyspepsia 2.
Consider steroid-sparing agents if:
- Patient required ≥2 courses of corticosteroids in the past year 2
- Patient becomes corticosteroid-dependent 2
- Taper is unsuccessful 1
In these scenarios, escalate to thiopurines, anti-TNF therapy, vedolizumab, ustekinumab, JAK inhibitors, or S1P modulators 2.
Alternative for Patients Wishing to Avoid Systemic Steroids
Beclomethasone dipropionate 5 mg once daily or budesonide MMX 9 mg once daily can be considered for mild-to-moderate disease in patients preferring to avoid systemic corticosteroid effects 2, 1, 2. These topically-acting steroids have high first-pass metabolism and lower systemic exposure, though they are modestly less effective than prednisolone.